Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Forecast to 2028

Report Code : BMIRE00026302 | Region : LAMEA | Industry : Pharmaceuticals | Published Date : 26/Sep/2022
Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (9-valent HPV Vaccine, Quadrivalent HPV Vaccine, and Bivalent HPV Vaccine), Dosage (2 Dose and 3 Dose), Age (9 to 14 Years and 15 to 45 Years), Application (HPV-Attributable Cancer and Genital Warts), and End User (Doctors Office, Community Health Clinics, School-based Health Centers, Health Departments, Hospitals, and Others)

The MEA human papillomavirus (HPV) vaccine market is expected to grow from US$ 82.91 million in 2022 to US$ 100.86 million by 2028; it is estimated to grow at a CAGR of 3.3% from 2022 to 2028.

Healthcare organizations have developed and adopted several strategies to prevent and eliminate HPV infections. The World Health Assembly, in August 2020, adopted the strategy for cervical cancer elimination. As per the strategy, to eliminate cervical cancer, all countries across the region must reach and maintain an incidence rate of below four per 100,000 women. To reduce the incidence rate of cervical cancer, countries should focus on vaccination, screening, and treatment of cervical cancer. In 2016, Gavi Board initiated an HPV vaccine program. That allows countries in their first year of the program to scale up and vaccinate girls between the age of 9 and 14 years. Through this new strategy, Gavi aimed to protect about 40 million girls from cervical cancer by 2020, preventing an estimated 900,000 deaths. Many countries accepted the Gavi support and introduced the HPV vaccine in their national immunization program. Countries with the highest burden of cervical cancer, initiated the Gavi HPV vaccine program. All these initiatives are aiding the HPV vaccines market substantially across the region.

With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the MEA human papillomavirus (HPV) vaccine market . The MEA human papillomavirus (HPV) vaccine market is expected to grow at a good CAGR during the forecast period.

MEA Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

MEA Human Papillomavirus (HPV) Vaccine Market Segmentation

The MEA human papillomavirus (HPV) vaccine market is segmented based on type, dosage, age, application, end user, and country. Based on type, the MEA human papillomavirus (HPV) vaccine market is segmented into 9-valent HPV vaccine, quadrivalent HPV vaccine, and bivalent HPV vaccine. The quadrivalent HPV vaccine segment dominated the market in 2022. Based on dosage, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 2 dose and 3 dose. The 2 dose segment dominated the market in 2022. Based on age, the MEA human papillomavirus (HPV) vaccine market is bifurcated into 9 to 14 years and 15 to 45 years. The 9 to 14 years segment dominated the market in 2022. Based on application, the MEA human papillomavirus (HPV) vaccine market is bifurcated into HPV-attributable cancer and genital warts. The HPV-attributable cancer segment dominated the market in 2022. Based on end user, the MEA human papillomavirus (HPV) vaccine market is segmented into doctors office, community health clinics, school-based health centers, health departments, hospitals, and others. The hospitals segment dominated the market in 2022. Based on country, the MEA human papillomavirus (HPV) vaccine market has been categorized into Saudi Arabia, South Africa, the UAE, Iran, Turkey, Kuwait, Bahrain, Egypt, and the Rest of MEA. Saudi Arabia would dominate the market in 2022.

GlaxoSmithKline plc.; Inovio Pharmaceuticals; Merck & Co., Inc.; R-Pharm; Sanofi; Serum Institute of India Pvt. Ltd; and Walvax Biotechnology Co., Ltd. are among the leading companies in the MEA human papillomavirus (HPV) vaccine market.

The List of Companies - Middle East & Africa Human Papillomavirus (HPV) Vaccine Market

● GlaxoSmithKline plc.

● Inovio Pharmaceuticals

● Merck & Co., Inc.

● R-Pharm

● Sanofi     

● Serum Institute of India Pvt. Ltd   

● Walvax Biotechnology Co., Ltd.

TABLE OF CONTENTS

1. Introduction

1.1 Study Scope

1.2 The Insight Partners Research Report Guidance

1.3 Market Segmentation

1.3.1 MEA Human Papillomavirus (HPV) Vaccines Market – By Type

1.3.2 MEA Human Papillomavirus (HPV) Vaccines Market – By Dosage

1.3.3 MEA Human Papillomavirus (HPV) Vaccines Market – By Age

1.3.4 MEA Human Papillomavirus (HPV) Vaccines Market – By Application

1.3.5 MEA Human Papillomavirus (HPV) Vaccines Market – By Distribution Channel

1.3.6 MEA Human Papillomavirus (HPV) Vaccines Market – By Country

2. Key Takeaways

3. Research Methodology

3.1 Coverage

3.2 Secondary Research

3.3 Primary Research

4. MEA Human Papillomavirus (HPV) Vaccine Market – Market Landscape

4.1 Overview

4.2 MEA PEST Analysis

4.3 Experts Opinion

5. MEA Human Papillomavirus (HPV) Vaccine Market – Key Market Dynamics

5.1 Market Drivers

5.1.1 Increase in Prevalence of HPV Associated Diseases

5.1.2 Initiatives Taken by Health Organizations

5.2 Market Restraints

5.2.1 High Cost of HPV Vaccines

5.3 Future Trends

5.3.1 Advancements in HPV Diagnostics Tests

5.4 Impact Analysis

6. Human Papillomavirus (HPV) Vaccine Market– MEA Analysis

6.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Forecast and Analysis

7. MEA Human Papillomavirus (HPV) Vaccine Market Analysis – By Type

7.1 Overview

7.2 By Type: Market Revenue and Forecast Analysis (US$ Million)

7.3 9-valent HPV vaccine

7.3.1 Overview

7.3.2 9-valent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

7.4 Quadrivalent HPV vaccine

7.4.1 Overview

7.4.2 Quadrivalent HPV vaccine Market Revenue and Forecast to 2028 (US$ Million)

7.5 Bivalent HPV Vaccine

7.5.1 Overview

7.5.2 Bivalent HPV Vaccine Market Revenue and Forecast to 2028 (US$ Million)

8. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Dosage

8.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Dosage (2022 and 2028)

8.2 2 Dose

8.2.1 Overview

8.2.2 2 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

8.3 3 Dose

8.3.1 Overview

8.3.2 3 Dose: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

9. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Age

9.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Age (2022 and 2028)

9.2 9 to 14 Years

9.2.1 Overview

9.2.2 9 to 14 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

9.3 to 45 Years

9.3.1 Overview

9.3.2 to 45 Years: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

10. MEA Human Papillomavirus (HPV) Vaccine Market Analysis - By Application

10.1 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by Application (2022 and 2028)

10.2 HPV-attributable Cancer

10.2.1 Overview

10.2.2 HPV-attributable Cancer: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

10.3 Genital Warts

10.3.1 Overview

10.3.2 Genital Warts: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

11. MEA Human Papillomavirus (HPV) Vaccine Market Analysis – By End User

11.1 Overview

11.2 MEA Human Papillomavirus (HPV) Vaccine Market Revenue Share, by End User (2022 and 2028)

11.3 Doctor Office

11.3.1 Overview

11.3.2 Doctor Office Market Revenue and Forecast to 2028 (US$ Million)

11.4 Community Health Clinics

11.4.1 Overview

11.4.2 Community Health Clinics Market Revenue and Forecast to 2028 (US$ Million)

11.5 School-based Health Centers

11.5.1 Overview

11.5.2 School-based Health Centers Market Revenue and Forecast to 2028 (US$ Million)

11.6 Health Departments

11.6.1 Overview

11.6.2 Health Departments Market Revenue and Forecast to 2028 (US$ Million)

11.7 Hospitals

11.7.1 Overview

11.7.2 Hospitals Market Revenue and Forecast to 2028 (US$ Million)

11.8 Others

11.8.1 Overview

11.8.2 Others Market Revenue and Forecast to 2028 (US$ Million)

12. MEA Human Papillomavirus (HPV) Vaccine Market - Country Analysis

12.1 Overview

12.1.1 MEA: Human Papillomavirus (HPV) Vaccine Market, by Country, 2022 & 2028 (%)

12.1.1.1 UAE: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.1 Overview

12.1.1.1.2 UAE: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.1.3 UAE: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.1.1.4 UAE: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.1.1.5 UAE: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.1.1.6 UAE: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.1.1.7 UAE: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.1.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.1 Overview

12.1.1.2.2 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.2.3 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.1.2.4 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.1.2.5 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.1.2.6 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.1.2.7 Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.1.3 South Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.1 Overview

12.1.1.3.2 South Africa: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.3.3 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.1.3.4 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.1.3.5 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.1.3.6 South Africa: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.1.3.7 South Africa: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.1.4 Iran: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.1 Overview

12.1.1.4.2 Iran: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.4.3 Iran: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.1.4.4 Iran: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.1.4.5 Iran: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.1.4.6 Iran: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.1.4.7 Iran: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.1.5 Turkey: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.1 Overview

12.1.1.5.2 Turkey: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.5.3 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.1.5.4 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.1.5.5 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.1.5.6 Turkey: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.1.5.7 Turkey: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.1.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.1 Overview

12.1.1.6.2 Kuwait: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.6.3 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.1.6.4 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.1.6.5 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.1.6.6 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.1.6.7 Kuwait: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.1.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.1 Overview

12.1.1.7.2 Bahrain: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.7.3 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.1.7.4 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.1.7.5 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.1.7.6 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.1.7.7 Bahrain: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.1.8 Egypt: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.1 Overview

12.1.1.8.2 Egypt: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.8.3 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.1.8.4 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.1.8.5 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.1.8.6 Egypt: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.1.8.7 Egypt: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

12.1.1.9 Rest of Middle the East and Africa: Human Papillomavirus (HPV) Vaccine Market Revenue and Forecast to 2028 (US$ Million)

12.1.1.9.1 Overview

12.1.1.9.2 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market – Revenue and Forecast to 2028 (US$ Million)

12.1.1.9.3 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Type, 2019–2028 (US$ Million)

12.1.1.9.4 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Dosage, 2019–2028 (US$ Million)

12.1.1.9.5 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Age, 2019–2028 (US$ Million)

12.1.1.9.6 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Application, 2019–2028 (US$ Million)

12.1.1.9.7 Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by End User, 2019–2028 (US$ Million)

13. Industry Landscape

13.1 Overview

13.2 Inorganic Growth Strategies

13.2.1 Overview

13.3 Organic Growth Strategies

13.3.1 Overview

14. Company Profiles

14.1 Merck & Co., Inc.

14.1.1 Key Facts

14.1.2 Business Description

14.1.3 Products and Services

14.1.4 Financial Overview

14.1.5 SWOT Analysis

14.1.6 Key Developments

14.2 GlaxoSmithKline plc.

14.2.1 Key Facts

14.2.2 Business Description

14.2.3 Products and Services

14.2.4 Financial Overview

14.2.5 SWOT Analysis

14.2.6 Key Developments

14.3 Serum Institute of India Pvt. Ltd

14.3.1 Key Facts

14.3.2 Business Description

14.3.3 Products and Services

14.3.4 Financial Overview

14.3.5 SWOT Analysis

14.3.6 Key Developments

14.4 Walvax Biotechnology Co., Ltd.

14.4.1 Key Facts

14.4.2 Business Description

14.4.3 Products and Services

14.4.4 Financial Overview

14.4.5 SWOT Analysis

14.4.6 Key Developments

14.5 Inovio Pharmaceuticals

14.5.1 Key Facts

14.5.2 Business Description

14.5.3 Products and Services

14.5.4 Financial Overview

14.5.5 SWOT Analysis

14.5.6 Key Developments

14.6 Sanofi

14.6.1 Key Facts

14.6.2 Business Description

14.6.3 Products and Services

14.6.4 Financial Overview

14.6.5 SWOT Analysis

14.6.6 Key Developments

14.7 R-Pharm

14.7.1 Key Facts

14.7.2 Business Description

14.7.3 Products and Services

14.7.4 Financial Overview

14.7.5 SWOT Analysis

14.7.6 Key Developments

15. Appendix

15.1 About The Insight Partners

15.2 Glossary of Terms

LIST OF TABLES.

Table 1.             MEA Human Papillomavirus (HPV) Vaccine Market, Revenue and Forecast, 2019–2028 (US$ Mn)

Table 2.             UAE Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 3.             UAE Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 4.             UAE Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 5.             UAE Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 6.             UAE Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 7.             Saudi Arabia: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 8.             Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 9.             Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 10.          Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 11.          Saudi Arabia Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 12.          South Africa: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 13.          South Africa Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 14.          South Africa Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 15.          South Africa Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 16.          South Africa Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 17.          Iran: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 18.          Iran Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 19.          Iran Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 20.          Iran Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 21.          Iran Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 22.          Turkey: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 23.          Turkey Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 24.          Turkey Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 25.          Turkey Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 26.          Turkey Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 27.          Kuwait: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 28.          Kuwait Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 29.          Kuwait Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 30.          Kuwait Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 31.          Kuwait Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 32.          Bahrain: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 33.          Bahrain Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 34.          Bahrain Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 35.          Bahrain Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 36.          Bahrain Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 37.          Egypt: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 38.          Egypt Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 39.          Egypt Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 40.          Egypt Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 41.          Egypt Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 42.          Rest of MEA: Human Papillomavirus (HPV) Vaccine Market, by Type – Revenue and Forecast to 2028 (US$ Million)

Table 43.          Rest of MEA Human Papillomavirus (HPV) Vaccine Market, by Dosage– Revenue and Forecast to 2028 (US$ Million)

Table 44.          Rest of MEA Human Papillomavirus (HPV) Vaccine Market, by Age– Revenue and Forecast to 2028 (US$ Million)

Table 45.          Rest of MEA Human Papillomavirus (HPV) Vaccine Market, by Application – Revenue and Forecast to 2028 (US$ Million)

Table 46.          Rest of MEA Human Papillomavirus (HPV) Vaccine Market, by End User – Revenue and Forecast to 2028 (US$ Million)

Table 47.          Recent Inorganic Growth Strategies

Table 48.          Recent Organic Growth Strategies

Table 49.          Glossary of Terms

The List of Companies - Middle East & Africa Human Papillomavirus (HPV) Vaccine Market

● GlaxoSmithKline plc.

● Inovio Pharmaceuticals

● Merck & Co., Inc.

● R-Pharm

● Sanofi     

● Serum Institute of India Pvt. Ltd   

● Walvax Biotechnology Co., Ltd.

Reason To Buy

● Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the MEA human papillomavirus (HPV) vaccine market.

● Highlights key business priorities in order to assist companies to realign their business strategies

● The key findings and recommendations highlight crucial progressive industry trends in the MEA human papillomavirus (HPV) vaccine market, thereby allowing players across the value chain to develop effective long-term strategies

● Develop/modify business expansion plans by using substantial growth offering developed and emerging markets

● Scrutinize in-depth MEA market trends and outlook coupled with the factors driving the human papillomavirus (HPV) vaccine market, as well as those hindering it

● Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

AVAILABLE CUSTOMIZATION RESEARCH METHODOLOGY REQUEST FOR TOC FREE SAMPLE REPORT
CHOOSE LICENCE TYPE
(Middle East & Africa Human Papillomavirus (HPV) Vaccine Market Forecast to 2028)
  • Single User Price $3,000$2,400
  • Site Price $4,000$3,200
  • Enterprise Price $5,000$4,000
Buy Now Add to Cart
REQUEST FOR TOC
SPEAK TO ANALYST
FREE SAMPLE
REPORT
INQUIRE BEFORE
BUYING
TOP
Quick Enquiry